These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9801489)

  • 1. Management of rHuEPO resistance in CRF patients: a clinical protocol at Winthrop-University Hospital.
    Trenkle JA
    ANNA J; 1998 Jun; 25(3):333-8, 344. PubMed ID: 9801489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to design an anemia management protocol.
    Senger JM; Trenkle JA; St John WD
    ANNA J; 1998 Apr; 25(2):235-40. PubMed ID: 9801503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia management protocols and epoetin alfa administration: an algorithm approach. Case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2002 Jun; 29(3):297-300. PubMed ID: 12164081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives: iron management during therapy with recombinant human erythropoietin.
    York S
    ANNA J; 1993 Dec; 20(6):645-50; quiz 651-2. PubMed ID: 8267408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case study of the anemic patient: epoetin alfa--focus on CQI and patient management.
    Kammerer JK
    ANNA J; 1994 Aug; 21(5):282-5. PubMed ID: 8080342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-erythropoietin-based anaemia management in chronic kidney disease.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to recombinant human erythropoietin in hemodialysis patients.
    Drüeke TB
    Am J Nephrol; 1990; 10 Suppl 2():34-9. PubMed ID: 2260616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Biochimie; 2016 Jun; 125():150-62. PubMed ID: 27039028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient.
    Bradley RR; Cunniff PJ; Pereira BJ; Jaber BL
    Am J Kidney Dis; 1999 Aug; 34(2):349-54. PubMed ID: 10430986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of renal anemia.
    Peco-Antic A
    Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possible role of soluble erythropoietin receptors in renal anemia].
    Sakaguchi M; Maeda Y; Naiki Y; Hasegawa H; Kanamaru A
    Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):524-9. PubMed ID: 12476588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
    Cotton SL; Holechek MJ
    ANNA J; 1989 Dec; 16(7):463-8. PubMed ID: 2604448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
    Abraham PA
    Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.